Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

GW Pharmaceuticals

A blockbuster deal announced earlier this week could be a sign of a bright future for cannabidiol-oriented pharmaceutical companies. On Wednesday, cancer therapy developer Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) struck a US$7.2 billion agreement with UK-based GW Pharmaceuticals PLC (NASDAQ:GWPH), makers of childhood epilepsy treatment Epidiolex, the first cannabis-based medicine approved in the US.

Cardiol CEO sees bright future for pharmaceutically produced cannabidiol after blockbuster Jazz-GW Pharmaceutical deal

The deal to buy GW Pharmaceuticals creates a leader in neuroscience.

Jazz Pharmaceuticals to Acquire Cannabis Drug Company

Aurora Cannabis

Aphria

Canopy Growth

Cronos Group

Tilray Brands

In a quiet market, marijuana companies stood out.

Pot Stocks Are Wednesday's Big Stock Market Winners. Will They Disappoint Shareholders in the End?

GW Pharmaceuticals (GWPH) stock is soaring higher on Wednesday following news that Jazz Pharmaceuticals (JAZZ) is acquiring the company. The post GWPH Stock: 12 Things to Know About the GW Pharma-Jazz Pharma Deal appeared first on InvestorPlace.

GWPH Stock: 12 Things to Know About the GW Pharma-Jazz Pharma Deal

Marijuana stocks rallied as Jazz Pharmaceuticals said it would buy GW Pharma. GWPH stock jumped.

Marijuana Stocks Rally As Jazz Pharma Agrees To Buy CBD Maker, Senate Majority Leader Schumer Backs Cannabis Reform

Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding a cannabis-based epilepsy treatment.

Jazz Pharma adds cannabis-based drug in $7.2 billion deal for GW Pharma

Dublin-based Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced Wednesday morning that it has agreed to acquire London-based GW Pharmaceuticals PLC (NASDAQ: GWPH) for $220 per American depositary share (ADS).

Cannabis-Derived Drug Maker GW Pharma Acquired by Jazz Pharma for $7.2 Billion

Medical cannabis stocks and stocks of cannabinoid drug companies are rallying big time Wednesday, the catalyst being a multi-billion-dollar buyout in the space.

CBD Drug Makers, Medical Cannabis Stocks Rally On GW Pharma's Big Buyout

GW Pharmaceuticals soared as much as 46% on Wednesday after Jazz Pharma said it would acquire the company for $7.2 billion in cash and stock. GW Pharma develops therapies derived from the marijuana plant. The UK-based company was the first to receive FDA approval for a cannabinoid-based therapy, Epidiolex, which is used to treat seizures in patients one-year and older.

GW Pharmaceuticals soars 46% after Jazz Pharma agrees to $7.2 billion acquisition of the medical-marijuana company (GWPH)

In the first big-ticket biopharma M&A of the year, Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced a deal to buy cannabinoid drug company GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH). The Jazz-GW Pharma Deal: Jazz announced a definitive agreement to buy GW Pharma for a total consideration of $220 per ADS in cash and stock, with $200 in cash and $20 in Jazz shares.

Jazz To Acquire Cannabinoid Drug Company GW Pharma For $7.2B

Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per share in cash and $20 in stock for each share owned, or a premium of about 50% over GW's closing price on Tuesday, and 60% over its 30-day volume weighted average price.

Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of...

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

AbbVie

Bristol-Myers

Elanco Animal Health Inc

Johnson & Johnson

Moderna

Pfizer

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

7 Pharmaceutical Stocks With Exciting Plans for 2021

DUBLIN, Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the...

Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug.

JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising

DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca™ (lurbinectedin) in combination with doxorubicin...

Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Down 3.7% Since Last Earnings Report: Can It Rebound?

Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Consider Jazz Pharmaceuticals (JAZZ) Stock?

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of Directors, effective December 1, 2020. "We are excited to welcome two industry leaders to the Board whose...

Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference: Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m....

Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ).

Were These Hedge Funds Right About Betting On Jazz Pharmaceuticals Plc (JAZZ)?

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with The University of Texas MD Anderson Cancer Center (MD Anderson), one abstract from a cooperative...

Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research

The shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are up 5.9% at $156 at last check, after a third-quarter earnings and revenue beat.

Pharma Stock Flies on Q3 Report, Analyst Praise

Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.

News for Jazz Pharmaceuticals Stock (JAZZ)